Eurobank’s 9-month decline, Q&R’s -11% and Evropharma’s negative streak

Eurobank’s 9-month decline, Q&R’s -11% and Evropharma’s negative streak

Posted on

9 months: Part of it comes from the worst session in the last 9 months Eurobank, which within a few hours lost 4.7%. And this, in fact, despite the first improvement from Moody’s double upgrade. Of course, the stock is still “running” on a rally + 27% in 2024 and + 34% in 12 months, remaining the most valuable bank with a value of 7.6 billion euros. At the same time, the distance from intra-session highs (2.2%) is only 7%.

Dive: Its stock reacted with a two-day dive of more than 11% Q&A to postpone the General Assembly again, but also to the imminent withdrawal of the proposal for the AMC, which is expected to be replaced by the end of a convertible bond loan. The new appointment for shareholders is scheduled for July 3. As a result of all this, the value of the listed company has doubled to 31 million euros, which is almost 30% away from this year’s peaks.

4×4: Its stock has successfully completed four consecutive negative meetings Cloud farms, which during this period of time lost almost 8% of its value, falling to 1.46 euros. This is the lowest level in the last 4 months. However, since the beginning of the year, the listed company still shows a return of more than 20%, which is largely due to improved profits.

Dividend: The green light for the distribution of a dividend of 0.08 euros/share (net value) or otherwise 9.6 million euros was given by ordinary GS to him Trade Estates AEEAP. Therefore, the cutoff will take place next Wednesday, while the payment of the money will start on June 26. As for the course of the board, the listed company is worth 200 million euros, measuring losses of almost 5% since the beginning of the year, clearly impacted by the broader sector discount.

Leave a Reply

Your email address will not be published. Required fields are marked *